Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture.

Trial Profile

Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Teriparatide (Primary) ; Risedronic acid
  • Indications Bone resorption; Male osteoporosis; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms MOVE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Oct 2015 Efficacy analysis (n=171) and 26 weeks interim results was presented at the 37th Annual Meeting of the American Society for Bone and Mineral Research
    • 04 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top